It was more than 80 percent correct in spotting cancerous nodules, but accuracy still needs improving
This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.
In trial, Mekinist and Tafinlar together seemed to perform better than Tafinlar alone, agency says
We care about your feedback. Let us know how we can improve your CancerCompass experience.